Agostini, Antonio
Guerriero, Ilaria
Piro, Geny
Quero, Giuseppe
Roberto, Luca
Esposito, Annachiara
Caggiano, Alessia
Priori, Lorenzo
Scaglione, Giulia
De Sanctis, Francesco
Sistigu, Antonella
Musella, Martina
Larghi, Alberto
Rizzatti, Gianenrico
Lucchetti, Donatella
Alfieri, Sergio
Sgambato, Alessandro
Bria, Emilio
Bizzozero, Laura
Arena, Sabrina
Ugel, Stefano
Corbo, Vincenzo
Tortora, Giampaolo
Carbone, Carmine
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (23681, 26330, 20583, 24519)
Agenzia Italiana del Farmaco, Ministero della Salute (J38D19000690001, 2019‐12369662)
Ministero dell'Università e della Ricerca (PRIN 2022 Prot. 2022P79F9N, PRIN 2022 PNRR Prot. P2022LN3KS, B39J22001200001, B33C22000630001)
Ministero dell’Istruzione, dell’Università e della Ricerca (B38D19000140006)
Article History
Received: 4 July 2023
Accepted: 13 November 2023
First Online: 23 November 2023
Declarations
:
: The experimental protocol was approved by the local ethics committee (Fondazione Policlinico Gemelli IRCCs, Ethical Committee approval Prot. Gen. 3536) and followed EU regulation. All patients gave consent to participate. All mouse models were housed and treated in accordance with the guidelines of the Institutional OPBA and Italian Ministry of Health Ethic Committee. The methods for animal study followed the ARRIVE Guidelines 2.0.
: All patients provided consent for publication.
: The authors have no competing interests to disclose.